PL2606125T3 - Charakterystyka i właściwości cytolityczne komórek eksprymujących th1 - Google Patents

Charakterystyka i właściwości cytolityczne komórek eksprymujących th1

Info

Publication number
PL2606125T3
PL2606125T3 PL11818884T PL11818884T PL2606125T3 PL 2606125 T3 PL2606125 T3 PL 2606125T3 PL 11818884 T PL11818884 T PL 11818884T PL 11818884 T PL11818884 T PL 11818884T PL 2606125 T3 PL2606125 T3 PL 2606125T3
Authority
PL
Poland
Prior art keywords
cells expressing
cytolytic properties
cytolytic
properties
expressing
Prior art date
Application number
PL11818884T
Other languages
English (en)
Polish (pl)
Inventor
Michael Har-Noy
Original Assignee
Immunovative Therapies, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies, Ltd. filed Critical Immunovative Therapies, Ltd.
Publication of PL2606125T3 publication Critical patent/PL2606125T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
PL11818884T 2010-08-20 2011-08-22 Charakterystyka i właściwości cytolityczne komórek eksprymujących th1 PL2606125T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40188110P 2010-08-20 2010-08-20
US201161495055P 2011-06-09 2011-06-09
PCT/US2011/048578 WO2012024666A2 (en) 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties
EP11818884.6A EP2606125B1 (en) 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties

Publications (1)

Publication Number Publication Date
PL2606125T3 true PL2606125T3 (pl) 2018-05-30

Family

ID=45594250

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11818884T PL2606125T3 (pl) 2010-08-20 2011-08-22 Charakterystyka i właściwości cytolityczne komórek eksprymujących th1

Country Status (19)

Country Link
US (3) US20120045423A1 (OSRAM)
EP (1) EP2606125B1 (OSRAM)
JP (2) JP6408219B2 (OSRAM)
KR (1) KR101900807B1 (OSRAM)
CN (2) CN103068973A (OSRAM)
AU (1) AU2011291477B2 (OSRAM)
BR (1) BR112013003989B1 (OSRAM)
CA (1) CA2808873C (OSRAM)
DK (1) DK2606125T3 (OSRAM)
ES (1) ES2660577T3 (OSRAM)
HU (1) HUE036094T2 (OSRAM)
IL (1) IL224813B (OSRAM)
NO (1) NO2606125T3 (OSRAM)
PH (1) PH12013500519B1 (OSRAM)
PL (1) PL2606125T3 (OSRAM)
PT (1) PT2606125T (OSRAM)
SG (2) SG10201510524TA (OSRAM)
TR (1) TR201802334T4 (OSRAM)
WO (1) WO2012024666A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011291477B2 (en) 2010-08-20 2016-07-28 Immunovative Therapies, Ltd. Cells expressing Th1 characteristics and cytolytic properties
KR101697473B1 (ko) * 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
RU2749113C2 (ru) 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
WO2018217064A2 (ko) 2017-05-26 2018-11-29 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 자연살해세포의 배양방법
SG11202104662UA (en) 2018-11-14 2021-06-29 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t-cells
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的t細胞の製造方法
US11730313B2 (en) * 2021-02-24 2023-08-22 Kirsten Wilkins Slow cooker liner system with integrated dividers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050392A1 (en) * 1998-09-22 2003-03-13 Brother Kogyo Kabushiki Kaisha Water-based ink for ink jetting and ink jet recording method
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
WO2003024312A2 (en) 2001-09-17 2003-03-27 Valeocyte Therapies Llc Cell therapy system
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
CA2535952A1 (en) 2002-08-23 2004-03-04 Gabriele Multhoff Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
EP1776583A4 (en) * 2004-02-26 2009-04-29 Immunovative Therapies Ltd PROCESSES FOR THE PREPARATION OF T CELLS FOR CELL THERAPY
AU2011291477B2 (en) 2010-08-20 2016-07-28 Immunovative Therapies, Ltd. Cells expressing Th1 characteristics and cytolytic properties

Also Published As

Publication number Publication date
CN103068973A (zh) 2013-04-24
CA2808873A1 (en) 2012-02-23
EP2606125A2 (en) 2013-06-26
HUE036094T2 (hu) 2018-06-28
DK2606125T3 (en) 2018-03-05
PH12013500519A1 (en) 2013-05-06
NO2606125T3 (OSRAM) 2018-04-21
CN108245673A (zh) 2018-07-06
JP2017061558A (ja) 2017-03-30
PH12013500519B1 (en) 2020-06-26
US20120045423A1 (en) 2012-02-23
US20130195825A1 (en) 2013-08-01
BR112013003989B1 (pt) 2020-11-24
CA2808873C (en) 2020-02-18
IL224813B (en) 2020-06-30
KR20130103485A (ko) 2013-09-23
EP2606125A4 (en) 2014-03-19
JP2013536232A (ja) 2013-09-19
BR112013003989A2 (pt) 2017-11-14
US20130196428A1 (en) 2013-08-01
JP6525946B2 (ja) 2019-06-05
US10385315B2 (en) 2019-08-20
WO2012024666A3 (en) 2012-05-18
SG10201510524TA (en) 2016-01-28
AU2011291477A1 (en) 2013-04-04
PT2606125T (pt) 2018-02-27
SG187846A1 (en) 2013-03-28
EP2606125B1 (en) 2017-11-22
AU2011291477B2 (en) 2016-07-28
TR201802334T4 (tr) 2018-03-21
WO2012024666A2 (en) 2012-02-23
ES2660577T3 (es) 2018-03-23
KR101900807B1 (ko) 2018-11-08
JP6408219B2 (ja) 2018-10-17

Similar Documents

Publication Publication Date Title
IL221511A (en) Arilatriazolones associated with bis aryl and their use
IL249669B (en) Converted 5-fluoro-h1-pyrazolopyridines and their use
PL2606120T3 (pl) Ludzkie komórki ułatwiające tolerancję i ich zastosowanie
ZA201208173B (en) Peptices and their use
IL226904A (en) Inganol-3-acetylates iii and Inganol-3-carbamates
GB201012175D0 (en) Procedure and mechanisms
IL223191A0 (en) Diversion-resistant microgranules and microtablets
PH12013500698A1 (en) Hair-mending compositions and associated methods
GB201300849D0 (en) Improvements in and relating to anti back-drive couplings
PL2605757T3 (pl) Preparaty oparte na nalbufinie i ich zastosowania
ZA201406726B (en) Methods and composition related to brown adipose-like cells
EP2622029A4 (en) PRINTING COLORING COMPOSITIONS AND METHOD FOR THEIR USE
SG10201510524TA (en) Cells expressing th1 characteristics and cytolytic properties
HUE041512T2 (hu) Új kombináció és alkalmazás
PT2563806E (pt) Leucolectinas humanas e suas utilizações
GB201018650D0 (en) Methods and compositions
GB201017820D0 (en) Cells and devices
IL222379A0 (en) Kras primers and probes
SG10201506940UA (en) Thioesterases and their use
GB201001384D0 (en) Light-fitting and associated methods
GB201117299D0 (en) Zinc-oxygen cell and its application
GB201020268D0 (en) Composition and uses
ZA201104629B (en) Closure and closure arrangement
GB201018651D0 (en) Methods and compositions
GB201009767D0 (en) Compositions and methods